TrialExpert opinion on biological therapy2021

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.

Suresh Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.